Analysis of Quality of Life (QOL) from the phase 3 randomized first-line indolent trial in patients with advanced follicular lymphoma receiving consolidation therapy with 90Y-ibritumomab tiuxetan : Abs.0802

---

Autoria(s): D'Amore F.; Valderrama A.; Gonzalez Diaz M.; O'Rourke N.; Petrini M.; Sebban C.; Zinzani P.L.; Gomes de Silva M.; Ketterer N.; Hagenbeek A.

Data(s)	2008
Identificador	http://serval.unil.ch/?id=serval:BIB_391A0052EE30 isbn:0390-6078
Idioma(s)	en
Fonte	13th Congress of the European Hematology Association
Tipo	info:eu-repo/semantics/conferenceObject inproceedings